Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher P Denton

Showing results (71-80 of 484) with videos related to

Pageof 49
Sort By:
Arthritis & Rheumatology (Hoboken, N.J.)|November 18, 2017
Review: Defining a Unified Vascular Phenotype in Systemic SclerosisYannick Allanore, Oliver Distler, Marco Matucci-Cerinic, et al.
Plos One|July 29, 2015
Partially Evoked Epithelial-Mesenchymal Transition (EMT) Is Associated with Increased TGFβ Signaling within Lesional Scleroderma SkinJoanna Nikitorowicz-Buniak, Christopher P Denton, David Abraham, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 20, 2016
ReplyVincent Sobanski, Jonathan Giovannelli, Christopher P Denton, et al.
Medical Hypotheses|June 3, 2018
Should all digital ulcers be included in future clinical trials of systemic sclerosis-related digital vasculopathy?Michael Hughes, Andrea Murray, Christopher P Denton, et al.
The Journal of Rheumatology|September 17, 2010
Characteristics of patients with juvenile onset systemic sclerosis in an adult single-center cohortIvan Foeldvari, Svetlana I Nihtyanova, Angela Wierk, et al.
Autoimmunity Reviews|February 19, 2017
Towards developing criteria for scleroderma renal crisis: A scoping reviewSabrina Hoa, Edward P Stern, Christopher P Denton, et al.
Journal of Scleroderma and Related Disorders|April 6, 2022
Rationale for the evaluation of nintedanib as a treatment for systemic sclerosis-associated interstitial lung diseaseLutz Wollin, Jörg Hw Distler, Christopher P Denton, et al.
Seminars in Arthritis and Rheumatism|January 20, 2024
Baseline absolute monocyte count predicts lung function decline among patients with systemic sclerosis-associated interstitial lung disease: A post hoc analysis from the focuSSced trialElana J Bernstein, Christopher P Denton, Suiyuan Huang, et al.
Rheumatology (Oxford, England)|June 22, 2012
Sustained improvement of diffuse systemic sclerosis following human cytomegalovirus infection offers insight into pathogenesis and therapyPia Moinzadeh, Korsa Khan, Voon H Ong, et al.
Clinical and Experimental Rheumatology|May 19, 2011
Recent advances in the diagnosis and treatment of interstitial lung disease in systemic sclerosis (scleroderma): a reviewAaron Tan, Christopher P Denton, Dimitri P Mikhailidis, et al.
Pageof 49

Showing results (71-80 of 484) with videos related to

Sort By:
Pageof 49
Arthritis & Rheumatology (Hoboken, N.J.)|November 18, 2017
Review: Defining a Unified Vascular Phenotype in Systemic SclerosisYannick Allanore, Oliver Distler, Marco Matucci-Cerinic, et al.
Plos One|July 29, 2015
Partially Evoked Epithelial-Mesenchymal Transition (EMT) Is Associated with Increased TGFβ Signaling within Lesional Scleroderma SkinJoanna Nikitorowicz-Buniak, Christopher P Denton, David Abraham, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 20, 2016
ReplyVincent Sobanski, Jonathan Giovannelli, Christopher P Denton, et al.
Medical Hypotheses|June 3, 2018
Should all digital ulcers be included in future clinical trials of systemic sclerosis-related digital vasculopathy?Michael Hughes, Andrea Murray, Christopher P Denton, et al.
The Journal of Rheumatology|September 17, 2010
Characteristics of patients with juvenile onset systemic sclerosis in an adult single-center cohortIvan Foeldvari, Svetlana I Nihtyanova, Angela Wierk, et al.
Autoimmunity Reviews|February 19, 2017
Towards developing criteria for scleroderma renal crisis: A scoping reviewSabrina Hoa, Edward P Stern, Christopher P Denton, et al.
Journal of Scleroderma and Related Disorders|April 6, 2022
Rationale for the evaluation of nintedanib as a treatment for systemic sclerosis-associated interstitial lung diseaseLutz Wollin, Jörg Hw Distler, Christopher P Denton, et al.
Seminars in Arthritis and Rheumatism|January 20, 2024
Baseline absolute monocyte count predicts lung function decline among patients with systemic sclerosis-associated interstitial lung disease: A post hoc analysis from the focuSSced trialElana J Bernstein, Christopher P Denton, Suiyuan Huang, et al.
Rheumatology (Oxford, England)|June 22, 2012
Sustained improvement of diffuse systemic sclerosis following human cytomegalovirus infection offers insight into pathogenesis and therapyPia Moinzadeh, Korsa Khan, Voon H Ong, et al.
Clinical and Experimental Rheumatology|May 19, 2011
Recent advances in the diagnosis and treatment of interstitial lung disease in systemic sclerosis (scleroderma): a reviewAaron Tan, Christopher P Denton, Dimitri P Mikhailidis, et al.
Pageof 49